In certain embodiments a dental strip for the prevention or reduction of dental caries is provided. In certain embodiments the dental strip is constructed to deliver effective amounts of specifically targeted antimicrobial peptides (or simple antimicrobial peptides) and comprises an orally compatible backing layer, a delivery layer disposed on one surface of the backing layer where the delivery layer comprises an orally compatible polymer, or combination of polymers, and a specifically targeted antimicrobial peptide (and/or simple antimicrobial peptide) capable of binding and killing Streptococcus mutans. In certain embodiments the dental strip additionally comprises a release liner.

In certain embodiments a dental strip for the prevention or reduction of dental caries is provided. In certain embodiments the dental strip is constructed to deliver effective amounts of specifically targeted antimicrobial peptides (or simple antimicrobial peptides) and comprises an orally compatible backing layer, a delivery layer disposed on one surface of the backing layer where the delivery layer comprises an orally compatible polymer, or combination of polymers, and a specifically targeted antimicrobial peptide (and/or simple antimicrobial peptide) capable of binding and killing Streptococcus mutans. In certain embodiments the dental strip additionally comprises a release liner.

The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.

A method of providing sustained-release topical treatment of a condition affecting an internal body cavity is provided. The method comprises administering a pharmaceutical composition comprising a thermoreversible hydrogel and an active pharmaceutical ingredient to an internal body cavity of the urinary tract. After administration, the concentration of the active pharmaceutical ingredient in urothelium of the internal body cavity is increased when compared to the concentration of the active pharmaceutical ingredient in urothelium of the internal body cavity following administration of a control composition comprising the same dose and concentration of active pharmaceutical ingredient in water.

A method of providing sustained-release topical treatment of a condition affecting an internal body cavity is provided. The method comprises administering a pharmaceutical composition comprising a thermoreversible hydrogel and an active pharmaceutical ingredient to an internal body cavity of the urinary tract. After administration, the concentration of the active pharmaceutical ingredient in urothelium of the internal body cavity is increased when compared to the concentration of the active pharmaceutical ingredient in urothelium of the internal body cavity following administration of a control composition comprising the same dose and concentration of active pharmaceutical ingredient in water.

Systems and methods for delivering active ingredients, such as pharmaceutically active ingredients, to substrates are described herein. The active ingredients are delivered as fluids to a fluiddispensing device for the creation of one or more drops for deposition onto substrates such as for the creation of microdoses. The invention further includes microdoses made by such processes.

Systems and methods for delivering active ingredients, such as pharmaceutically active ingredients, to substrates are described herein. The active ingredients are delivered as fluids to a fluiddispensing device for the creation of one or more drops for deposition onto substrates such as for the creation of microdoses. The invention further includes microdoses made by such processes.

Compositions and methods for improving nitric oxide levels in a subject, comprising administering to a subject, a composition comprising dietary nitrate derived from potassium nitrate, beet root (whole plant, powder, plant extract), and/or nitrate-rich leafy green portions (whole plant, powder, plant extract) that improve functional nitric oxide levels in subjects as shown by increasing salivary bioconversion of nitrate to nitrite, a necessary a required step for nitric oxide mediated health benefits. The disclosed novel compositions improve cardiac health, lowers blood pressure, intraocular pressure, and LDL and restores nitric oxide mediated cardiovascular benefits, including but not limited, restoring endothelium function and improving flow mediated dilation.

Compositions and methods for improving nitric oxide levels in a subject, comprising administering to a subject, a composition comprising dietary nitrate derived from potassium nitrate, beet root (whole plant, powder, plant extract), and/or nitrate-rich leafy green portions (whole plant, powder, plant extract) that improve functional nitric oxide levels in subjects as shown by increasing salivary bioconversion of nitrate to nitrite, a necessary a required step for nitric oxide mediated health benefits. The disclosed novel compositions improve cardiac health, lowers blood pressure, intraocular pressure, and LDL and restores nitric oxide mediated cardiovascular benefits, including but not limited, restoring endothelium function and improving flow mediated dilation.

An implant for the control of parasites in livestock comprising an isoxazoline compound of Formula (I)

##STR00001## or salt or solvate thereof, wherein the implant comprises one or more pellets each of which comprises the isoxaxoline compound and a pharmaceutically acceptable excipient and a method of preventing or treating a parasite infestation using the same.